Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

Navigation breadcrumbs

  1. Home
  2. Latest
  3. Dr Chris Laing appointed as new UCLPartners Chief Executive Officer

Dr Chris Laing appointed as new UCLPartners Chief Executive Officer

3 February 2022
New Chief Executive Officer Dr Chris Laing will lead our work as a partnership to improve the health of our population through the implementation of research and innovation into practice.

We are delighted to announce the appointment of Dr Chris Laing as Chief Executive Officer of UCLPartners.

Chris will lead our work as a partnership to improve the health of our population through the implementation of research and innovation into practice. He takes up the role with immediate effect.

Chris has been Director of our Academic Health Science Network and National Director of the NHS Innovation Accelerator since October 2021. He joined us from University College London Hospitals NHS Foundation Trust and Royal Free London NHS Foundation Trust, where he continues to practise as a consultant nephrologist. He is also Honorary Associate Professor of Nephrology at the UCL Centre for Nephrology.

Richard Murley, Chair of UCLPartners said: “The Board is delighted to appoint Chris to realise the ambitions of the partnership. With his extensive experience in transformation, innovation and clinical care, Chris is ideally placed to realise the significant collective potential of our partnership to improve the health and wellbeing of our population.”

Commenting on his appointment, Chris said: “I feel honoured to be stepping into this role. I am committed to working across our partnership – with health and care providers, integrated care systems, universities, patients and the public, industry, charities, local authorities and others. By working together, we can drive research translation and innovation adoption to deliver significant, measurable improvement in the health of our population.”